You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site.


Go back

woman stretching
The safety profile of Relvar

Relvar: well tolerated in asthma and COPD, with over 5 million patient-years of exposure1,2

Relvar has a generally well-tolerated safety profile2 with adverse events consistent with the ICS/LABA class of medications.2

See below for a brief summary of adverse events associated with Relvar. Full details can be found in the Relvar Summary of Product Characteristics.

Very common adverse events (≥1/10)⁴

Common adverse events (≥1/100 to <1/10)⁴

  • Headache
  • Nasopharyngitis
  • Pneumonia
  • Upper respiratory tract infections
  • Bronchitis
  • Influenza
  • Candidiasis of mouth and throat
  • Oropharyngeal pain
  • Pharyngitis
  • Rhinitis
  • Sinusitis
  • Cough
  • Dysphonia
  • Abdominal pain
  • Arthralgia
  • Back pain
  • Fractures
  • Pyrexia
  • Muscle spasm

Pneumonia risk in asthma4

Pneumonia risk in COPD4

In an integrated analysis of 11 studies asthma (n=7034), the incidence of pneumonia per 1000 patient-years was 18.4 for Relvar 184/22 mcg vs. 9.6 for Relvar 92/22 mcg and 8.0 for placebo2 In common with other ICS-containing medicines, there is an increased risk of pneumonia in COPD patients treated with these types of medicines. The incidence of pneumonia with Relvar is similar to that seen with other ICS/LABA combinations3

Discover Relvar

Happy senior male wear glasses relaxing and breathing fresh air at park
Breathing Space

From educational videos to podcasts, Breathing Space is a GSK initiative designed to share the latest thinking on lung health and provide a space for pulmonologists and other respiratory specialists to gather insights and explore best practice.


*If using on average two doses per day.


COPD, chronic obstructive pulmonary disorder; ICS, inhaled corticosteroid; LABA, long-acting β2-agonist. 

  1. GSK Data on File 16221; 2019.
  2. Global Datasheet Fluticasone furoate/vilanterol: v11, May 2021.
  3. Kew KM, et al. Cochrane Syst Rev 2014;3:CD010115.
  4. Relvar Ellipta SmPC, 2021 available at

RELVAR Ellipta was created in collaboration with

Innoviva logo

Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

Relvar is a registered trademark of the GlaxoSmithKline group of companies

A.G. Last updated: May 2021 PM-IE-FFV-WCNT-210007